Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lp(a)FRONTIERS CAVS pelacarsen trial in calcific aortic valve stenosis
NL-OMON60971Phase 2Recruiting
- Sponsor
- Novartis
- Start
- Dec 2024
- Modality
- Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in calcific aortic stenosis (AS) comparing Pelacarsen with Placebo (2 arms). Primary endpoints: Change in peak aortic jet velocity from baseline to month 36 and Change in aortic valve calcium score from baseline to month 36. Started Dec 2024; status: recruiting.
02
Drugs
pelacarsen
03
Conditions
calcific aortic stenosis (AS)
Beyond the preview
Go deeper on NL-OMON60971.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60971.